Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL DEVICE NEWS IN BRIEF
September 16, 2002
- REGULATORY NEWS IN BRIEF
September 16, 2002
- Walgreens May Consider Entry into Japan If Bungyo Rate Exceeds 70%: Mr Burgess
September 16, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
September 16, 2002
- WORLD NEW IN BRIEF
September 16, 2002
- PRESS SEMINAR
September 16, 2002
- OTC NEWS IN BRIEF
September 16, 2002
- Basic Policy for GL for Physician-led Clinical Trials Presented
September 16, 2002
- BULLETIN
September 16, 2002
- Nihon Schering Aims at \100 Billion Sales in 2010: Mr Martino
September 16, 2002
- DIAGNOSTIC NEWS IN BRIEF
September 16, 2002
- Fujisawa's Restructuring to Make Operating Profit Ratio Increase to 18-20% in 2005
September 16, 2002
- BUSINESS NEWS IN BRIEF
September 16, 2002
- JPMA President Calls For Joint Effort of Industry, Government Based on Vision
September 16, 2002
- Kuraya Sanseido Passive on Promoting Generics
September 16, 2002
- SMONA Expands Business, Organization in the 2nd Year
September 16, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 9, 2002
- BUSINESS NEWS IN BRIEF
September 9, 2002
- REGULATORY NEWS IN BRIEF
September 9, 2002
- Korosho Requests Tax Reform to Beef Up Industry
September 9, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…